Clinical Trial

Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2026 (before its estimated March 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
Athletes often compete in the morning when they are biologically weaker; normally in competition heats or quarterfinals to qualify for the finals scheduled in the evening. Some athletes may even choose to perform at submaximal levels in these qualifying rounds, especially when they are expected to perform multiple times in the same day (such as weightlifting at the Olympic Games). Gross muscular performance such as power output or force production is greater in the evening than the morning (\~3-14% variation). Similarly, time-trial performance and repeated sprint performance (RSP; a good measure of performance in team sport) is \~3 and 5 % greater in the evening than the morning. The reason for this daily variation in performance is attributed to central factors (such as the body clock), as well as motivational and peripheral factors, including higher core and muscle temperatures in the evening compared to the morning. The body clock located within the anterior hypothalamus consists of a group of neurons known as suprachiasmatic nuclei, which are responsible for controlling the rhythm of core temperature. This 'master clock' has an endogenous period (\~24.2 h) slightly longer than the 24-h solar day; therefore, must be entrained by time cues (zeitgebers) to remain in sync with the environment, of these the light-dark cycle is the most powerful in humans. The most efficient nutritional ergogenic is caffeine. Recently caffeine has been investigated to reduce the negative influence of diurnal variations on repeated-sprint ability test (10 × 6 s cycle sprints, with 30 s of rest) at 60 min after ingestion of either 5 mg·kg-1 or placebo. A recent study reported that caffeine supplementation did not prevent the reduction in performance in the morning. However, placebo effect can be 3-5% and hence the use of a No-pill condition would ensure that any placebo effect is accounted for and that the true potential effect of caffeine can be established. To the best of our knowledge, no study has yet investigated a) caffeine (300 mg), NoPill or Placebo (300 mg dextrose) effects on cognitive and physiological morning performance.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-09.
Trial Details
NCT Number NCT07466732
Lead Sponsor Liverpool John Moores University
Conditions Caffeine, Placebo - Control, No Pill
Enrollment 15 participants
Start Date 2025-12-08
Primary Completion 2026-03-25 (estimated)
Study Completion 2026-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-13